Slides on Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice

Learn the data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.
John D. Baxter, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: January 24, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 14, 2022

Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 7, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

Prof Gail Matthews, MD, PhD Released: January 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings